KalVista Pharmaceuticals (KALV) News Today

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) shares dipped after quarterly results fell short of expectations, but analyst upgrades and strong early performance of its EKTERLY launch helped temper the decline.

• Positive Sentiment: Needham & Company reaffirmed its “buy” rating and set a $28.00 price target on KALV, implying nearly 100% upside from current levels. Benzinga
• Positive Sentiment: JMP Securities raised its price target on KALV from $27.00 to $28.00 and maintained a “market outperform” rating, also signaling substantial upside. Benzinga
• Positive Sentiment: KalVista reported a strong start to its EKTERLY launch in Q1, suggesting early commercial momentum for the company’s lead product. TipRanks
• Neutral Sentiment: Multiple Q1 2026 earnings call transcripts and presentations were released by Seeking Alpha, InsiderMonkey, Yahoo Finance and others, providing detailed operational and financial commentary. Seeking Alpha
• Negative Sentiment: KalVista reported Q1 EPS of –$1.12, missing the consensus of –$0.91, and Q1 revenue of $1.43 million versus estimates of $1.97 million. Zacks
• Negative Sentiment: CEO Benjamin Palleiko sold 7,294 shares at an average price of $15.84, trimming his holding by 1.8%. MarketBeat